South Africa Launches Patient-Led Cancer Registry

By Crystal Lubbe

March 4, 2025

Are we truly capturing the full landscape of cancer care in South Africa? South Africa has initiated a new approach to cancer data collection by introducing a patient-led cancer registry. This is in collaboration with the National Cancer Registry (NCR) and the non-governmental organization Living with Cancer South Africa. This initiative aims to fill data gaps and improve the accuracy of cancer statistics, which are currently limited by a pathology-based system that may miss diagnoses made outside laboratory settings.

Key Insights

Patients or their loved ones can now register cancer details online, providing a more comprehensive picture of cancer incidence in South Africa. The existing pathology-based system has been inadequate, particularly for cancers diagnosed through radiology, tumor markers, or clinical deduction rather than biopsies. Enhanced data will assist in better resource allocation and the development of data-driven cancer policies.  The new system also allows for recording historic cancer cases, including those of deceased individuals, to enrich the overall data.

Patient Cancer Registry

Established in 1986, the NCR has been the primary source of national cancer incidence data in South Africa. It uses a pathology-based surveillance system, which has limitations including heavy reliance on laboratory data and the potential to miss cases diagnosed through other methods. The use of both active and passive case-finding methods is crucial for improving the completeness and accuracy of cancer registry data. This is evidenced by other South African cancer registries like the Eastern Cape Cancer Registry. According to the World Health Organization, Africa faces a significant cancer burden, with around 1.1 million new cancer cases and 700,000 deaths annually. Accurate data collection through the patient-led cancer registry is essential for effectively addressing this crisis.

Health Implications

Improved cancer data will enable better resource allocation and more effective policy-making, enhancing cancer care and outcomes. This can optimize healthcare spending by targeting resources to areas with the highest need. Accurate and comprehensive data will aid in developing more targeted and effective cancer prevention and control strategies. Therefore, potentially leading to improved survival rates and better patient outcomes. Data-driven policies can be more effective in addressing the cancer burden. Involving patients in the reporting process ensures that policies are patient-centered and responsive to real-world needs.

By identifying and filling data gaps, South Africa can use its resources more efficiently. As a result, cancer care will become both accessible and effective across different regions and populations.

The patient-led cancer registry emphasises the importance of patient involvement in improving the accuracy and comprehensiveness of cancer data.

Reference url

Recent Posts

patient-led cancer registry
     

South Africa Launches Patient-Led Cancer Registry

📊 Are we truly capturing the full landscape of cancer care in South Africa?

A new patient-led cancer registry aims to transform data collection, empowering patients to report their diagnoses online. This initiative is set to fill critical gaps in current cancer statistics, enabling better resource allocation and improving cancer care policies.

Explore how patient involvement can reshape healthcare data in South Africa!

#SyenzaNews #HealthcareInnovation #HealthEconomics #resourceallocation

Fabhalta C3 glomerulopathy treatment
       

Fabhalta C3 glomerulopathy treatment Gains EMA Endorsement as First Targeted Therapy

💡 Have you heard the latest on treatment options for rare kidney diseases?

Novartis’ Fabhalta (iptacopan) has received a positive opinion from the EMA, potentially paving the way for the first approved treatment for C3 glomerulopathy. This first-in-class therapy showed a remarkable 35.1% reduction in proteinuria, promising improved outcomes for patients facing this progressive condition.

Curious about the implications for healthcare and the economy? Dive into the full article to learn how Fabhalta could reshape the landscape for patients with C3G and other complement-mediated diseases.

#SyenzaNews #HealthcareInnovation #DrugDevelopment #MarketAccess

TLX250-CDx imaging agent
      

Zircaix: A Potential Breakthrough in Kidney Cancer Diagnosis

🔍 Could a new imaging agent revolutionize kidney cancer diagnosis?

The FDA’s acceptance of the Biologics License Application for TLX250-CDx marks a significant milestone in the fight against clear cell renal cell carcinoma (ccRCC). This investigational PET imaging tool promises non-invasive, high-accuracy diagnostics, which could lead to improved patient outcomes and better-targeted treatment plans.

Curious about its potential impact on healthcare and market dynamics? Dive into the full article to learn more!

#SyenzaNews #medicalimaging #oncology #HealthcareInnovation

When you partner with Syenza, it’s like a Nuclear Fusion.

Our expertise are combined with yours, and we contribute clinical expertise and advanced degrees in health policy, health economics, systems analysis, public finance, business, and project management. You’ll also feel our high-impact global and local perspectives with cultural intelligence.

SPEAK WITH US

CORRESPONDENCE ADDRESS

1950 W. Corporate Way, Suite 95478
Anaheim, CA 92801, USA

© 2025 Syenza™. All rights reserved.